相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
Peter Ruf et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time
Milos Aleksic et al.
IMMUNITY (2010)
Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Newer monoclonal antibodies for hematological malignancies
Jorge Castillo et al.
EXPERIMENTAL HEMATOLOGY (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
P. Buehler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
CD3-specific antibodies: a portal to the treatment of autoimmunity
Lucienne Chatenoud et al.
NATURE REVIEWS IMMUNOLOGY (2007)
CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Michael Molhoj et al.
MOLECULAR IMMUNOLOGY (2007)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
B Schlereth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
T-cell antigen-receptor stoichiometry:: pre-clustering for sensitivity
B Alarcón et al.
EMBO REPORTS (2006)
Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum
ME Call et al.
EMBO JOURNAL (2004)
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
T Dreier et al.
JOURNAL OF IMMUNOLOGY (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Designing heterodimeric two-stranded α-helical coiled-coils -: Effects of hydrophobicity and α-helical propensity on protein folding, stability, and specificity
JR Litowski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
